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  Since their introduction to the United States in 2008, synthetic cannabinoids became the 
most widely used recreational drug behind marijuana, then regressed to an estimated prevalence 
of less than 1%. Contrary to expectations for a drug declining in use, emergency department 
presentations and acute poisonings related to the use of synthetic cannabinoids are increasing. 
Alongside this phenomenon, a growing body of literature is beginning to uncover a relationship 
between psychosis and synthetic cannabinoid use. A current gap in the literature exists 
surrounding harm prevention methods and targeted intervention strategies for users of synthetic 
cannabinoids. To date, no known studies have examined individuals with a history of use of 
these substances and investigated the reasons they decided to discontinue recreational use. The 
purpose of the current study was to fill this gap in the literature while also further confirming and 
expanding existing research on the characterization of synthetic substance use, perceived harm of 
synthetic cannabinoids, and users’ knowledge about synthetic cannabinoids. Cross sectional 
survey methods in a non-experimental comparative design was utilized with participants 
recruited through the online crowd sourcing platform Amazon MTurk. Significant motivating 
factors for both discontinuation and continuation of synthetic cannabinoid use were found 
including personal experience, accessibility, preference towards other substance, and questions 
surrounding the source and purity of the synthetic cannabinoids. It was also found that 
individuals who currently use synthetic cannabinoids have less general knowledge about the 
 
	 ii 
substance class when compared to individuals who have discontinued use. These results suggest 
that psychoeducational campaigning surrounding general knowledge about the substance class as 
well as information on the physiological effects of synthetic cannabinoids may be an effective 
harm reduction method.  
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INTRODUCTION TO THE PROBLEM 
Since the first synthetic drug, synthetized in 1869, an age of pharmaceutical chemistry 
has been ushered in providing unprecedented advances in the ability to treat diseases. However, 
much like their naturally occurring counterparts, synthetic pharmaceuticals also present the 
capacity for misuse and abuse. Famous synthetic or designer substances such as Lysergic Acid 
Diethylamide (LSD or Acid) first synthesized in 1938 or Methylenedioxymethamphetamine 
(MDMA or Ecstasy) first patented in 1914 both fueled a cultural revolution of drugs of abuse in 
society (Lee & Schlain, 1985; McDowell & Kleber, 1994). These substance, often revered in 
pop-culture, served as the precursor for the deluge of synthetic substances that are seen today.   
New legal forms of synthetic drugs are emerging at a rate faster than the current pace of 
research. The most widely known and thoroughly studied class of synthetic drugs are synthetic 
cannabinoid receptor agonists. These synthetic cannabinoids (SCs) were originally developed in 
the 1970s in an attempt to explore their pharmacological uses (Debruyne & Le Boisselier, 2015). 
Designed to mimic the effects of the primary psychoactive component of marijuana (Δ9-THC), 
SCs bind to the same CB1R and CB2R receptors as THC found in marijuana however at a much 
higher affinity (Castaneto et al., 2014, Deng, Verrico, Kosten, & Nielsen, 2018). These synthetic 
analogues can be as much as 2 – 100 times more potent than Δ9-THC (Riederer et al., 2016). The 
first synthetic cannabinoid analogue (HU-210) was synthesized in 1988, however since then 
many different synthetic cannabinoids have been isolated and five distinct categories were 
formed (Langford & Bolton, 2018). Twenty years later, the first synthetic cannabinoid to be 
detected in a smoking blend designed for recreational use was JWH-018 in 2008. Though 




on incidence of SC use did not begin until 2011 through the Monitoring the Future survey 
program (Vandry, Dunn, Fry, & Girling, 2012).  
When prevalence of SC usage first began being monitored in 2011, annual prevalence 
was found to be 11.4%, becoming the second most widely used class of drugs behind marijuana 
that year (Monitoring the Future, 2016). Though the exact causes are unknown, the overall 
prevalence of use has declined steadily since 2011 reaching annual prevalence rates as low as 1% 
in young adult populations (Schulenberg et al., 2016). Over time there has also been an increase 
in the perceived risk of using SCs. Though the decrease in prevalence of annual use and an 
increase in perceived risks involved with SC usage is promising, the rates of acute poisonings 
resulting from SC usage is increasing (Riederer et al., 2016). Though only one death has 
occurred with SCs being identified as a sole agent involved, systematic case studies of existing 
data have identified a strong correlation with SC usage and psychotic symptoms (Deng et al., 
2018). Though the role of SCs in psychosis is more complex than a single chemical component 
may explain, both new onset of psychotic symptoms as well as relapse of psychotic symptoms 
have been associated with SC use.  
A major challenge presented to all disciplines attempting to study the physiological and 
psychological effects of SCs are their difficulty to metabolically detect using both common and 
sophisticated screening methods. Common urinary analysis methods used for detection of drugs 
are not suitable for identification of SC use (Hu, Primack, Barnett, & Cook, 2011; Fantegrossi, 
Moran, Radominska-Pandya, & Prather, 2015; Debruyne & Boisselier, 2015; Hutter, Kneisel, 
Auwarter, Neukamm, 2012; Seeley, Lapoint, Moran, & Fattore, 2012). Though Hutter et al. 
(2012) developed procedural methods for detection of 22 different synthetic cannabinoids in 




presenting often to evade regulation present a notable challenge in detection and screening. Often 
once assay methods such as those by Hutter et al. (2012) have been developed to detect a variety 
of SCs, illicit laboratories have moved on to new compounds resulting in many months of delay 
before confirmatory tests for the new compounds become available (Trecki, Gerona, & 
Schwartz, 2015). Difficulty in detection has been identified as a motivation for use of SCs. 
Vandry et al. (2013) identified that 30% of their sample population endorsed achieving 
intoxication while evading detection in urinary analysis as a primary reason for use. When 
comparing usage patterns between SCs and marijuana, 14.5% of respondents who endorsed a 
preference towards SCs cited evasion of detection as their primary reason for preference 
(Winstock & Barratt, 2013). In a unique investigation of prevalence, it was identified that 4.5% 
of athletes subject to routine screening for substance use were using SCs presumably to evade 
detection (Heltsley et al., 2012). Avoidance of detection is one of several reasons that could be 
linked to usage of SCs.  
Another potential contribution to the rapid rise in SC use is its wide availability. Though 
legislation enacted shortly after the rise of SC use has reduced availability, initially herbal 
mediums containing SCs were available at gas stations, convenience stores, vape stores, tobacco 
stores, online, and shops that sell paraphernalia for tobacco and marijuana use (head shops) 
among others (Castellanos & Gralnik, 2016; Hudson & Ramsey, 2011; Spaderna, Addy, 
D’Souza, 2013). As personal vaporizers or “e-cigarettes” became increasingly popular as an 
alternative to tobacco use, SCs also became available in a liquid form that could be administrated 
through these devices (Debruyne & Le Boisselier, 2015; Trecki, et al. 2015). The Monitoring the 
Future survey project, while investigating perceived availability of other drugs, has not 




suggesting that availability may contribute to SC use. Cooper (2014) reported that 14% of 
individuals who do not use SC’s but have friends who engage in SC use identified low cost and 
availability as a factor motivating their peers’ use. Fattore and Fratta (2011) also discussed the 
ease of acquisition of SCs from online sources and local shops. The ability to easily acquire SCs 
through processes that are much safer than other illicit drugs may have contributed to their initial 
popularity and continued use.  
Another unique factor contributing to the rise of popularity in SCs were their legal status. 
It should come as no surprise that legal methods of intoxication are in great demand (United 
Nations Office on Drugs and Crime “UNODC”, 2018). Since their emergence in 2008 and prior 
to 2012, the legal status of these substances remained in flux. Pieces of state legislation were 
proposed to regulate the legal status of SCs, however SCs were often scheduled on a substance-
by-substance basis and easily skirted by reformulation (Debruyne & Le Boisselier, 2015). This 
legislation cascade was a contributory factor to the current multitude of different types of SCs 
that have been identified. To date, there have been 251 different SCs reported internationally by 
the United Nations Office on Drugs and Crime (2018), representing the largest category in terms 
of different substances reported. In 2012, the United States Congress passed the Synthetic Drug 
Abuse Prevention Act of 2012, effectively blanket scheduling SCs and allowing subsequent 
scheduling of new SC formulations under the auspices of The Federal Analogues Act.  Though it 
has reduced since 2012, the United States seized 5 tons of SCs in 2016 in response to the passing 
of this legislation (UNODC, 2018).  
Significance of the Problem 
 The population with the highest prevalence of use of SCs are high school aged men, 




acute poisonings, 27.4% of individuals requesting medical treatment after exposure to SCs were 
under 18 years of age (Riederer et al., 2016). Though there has been a notable drop in prevalence 
of use, these younger populations remain at high risk.  Acute poisonings as a result of SC usage 
is also increasing despite a drop in overall use. The first four months of 2015 showed a 330% 
increase in SC related calls to United States poison control centers (Riederer et al., 2016). 
However, because many presentations for psychiatric problems do not indicate assessment for 
SCs use, SC related emergency medical care may be seriously underreported (Tait et al., 2016).  
 There is a growing body of evidence suggesting a relationship between presentation of 
psychiatric symptoms and SC use (Fattore, 2016; Fattore & Fratta, 2011; Cooper, 2016; Trecki et 
al., 2015; Debruyne & Le Boisselier, 2015; Spaderma et al., 2013; Castellanos & Gralnik, 2015; 
Every-Palmer, 2010). It comes as little surprise as existing research has provided evidence to the 
association of adolescent marijuana use and likelihood of developing psychotic disorders later in 
life (Pierre, 2011). However, the psychotic symptoms associated with SC use are generally 
observed in instances of acute intoxication. It is currently unclear if SCs pose the same risks of 
increased chance of later development of psychotic disorders in the same way that marijuana 
does, especially with use during adolescence (Deng et al., 2018). SCs have also been shown to 
have the potential to trigger psychotic symptoms in individuals with a history of psychotic 
episodes (Seely, Lapoint, Moran, & Fattore, 2012).  
 There are compelling reasons to use SCs as a recreational substance. Low cost, 
availability, legal status, difficulty in screening/detection, and perceived safety are some 
contributing factors. A 3-gram packet of spice generally sells for about $30 - $40 and can be 
acquired through both retail and illicit channels (Spaderna et al., 2013). As discussed previously, 




widely available and add significant complexity and cost to extant drug screening protocols 
(Trecki et al., 2015). A survey conducted by Bonar, Ashrafioun, and Ilgen (2014) demonstrated 
that 30% of individuals who use SCs endorsed safety as a motivating factor. These factors, 
among others may be contributing to the current rise in acute intoxications and the increase in 
presentation of psychotic symptoms related to SC use. The U.S. Department of Health and 
Human Services has underscored the importance of the development of targeted prevention 
interventions for synthetic cannabinoids and the need for education on the consequences of using 
these substances (Riederer at al., 2016). 
Purpose of the Study 
 Synthetic cannabinoids briefly became the most commonly used recreational drug behind 
marijuana, and then in a span of 5-years had a reduction in prevalence to below 1%. Therefore, it 
seems plausible that there are significant contributing factors that may be able to explain this 
seemingly unusual rapid rise and fall of use of a drug. While some research has attempted to 
explain why individuals may be motivated to use SCs or may choose them as opposed to other 
substances, no known current research exists examining why prevalence has decreased so 
sharply in a relatively short period of time. Furthermore, while many studies and articles exist 
explaining the intricacies of the different SC formulations and their risks, no known research 
exists that examines end users individual knowledge about SCs and the potential for negative 
health effects.  
 An understanding of why individuals are choosing to discontinue or avoid use of SCs 
may be able to inform targeted intervention and prevention strategies as well as assist in the 
development of education programs on the potential consequences of SC use. Concurrently, an 




intervention and prevention strategies. Because SCs fall into a niche category as a synthetic 
analogue of a recreational drug that is already widely used, it is unclear if motivations 
surrounding the use of SCs are unique to this class or generalizable to other substances.  
 The purpose of the study was to develop an understanding of why individuals with a 
history of synthetic cannabinoid use have decided to either discontinue use of these substances or 
continue use. In addition, the study investigated general knowledge about synthetic cannabinoids 
of individuals with a history of use as well as investigating the perceived risks of synthetic 
cannabinoids relative to other drug classes. The research questions of this study are listed below.  
Research Questions 
1) What factors have motivated individuals to discontinue synthetic cannabinoid use? 
2) What factors contribute to the continued use of synthetic cannabinoids? 
3) What knowledge do individuals who currently use or have used synthetic cannabinoids 
possess on the physiological effects and known consequences of synthetic cannabinoid 
use? 
4) What are the perceived risks of using synthetic cannabinoids? 
Definition of Terms 
1) CB1R & CB2R Receptors: Receptors located in the central and peripheral nervous 
system (CB1R) and in the immune system (CB2R). These receptors are the targets with 
which synthetic cannabinoids interact and elicit cannabimimetic effects similar to that of 
Δ9-tetrahydrocannabinol (THC). (Castaneto et al., 2014).  
2) Δ9-THC: The primary psychoactive compound found in marijuana which recreational 






 The present study investigated the reasons that individuals decide to discontinue using 
synthetic cannabinoids, continue to use synthetic cannabinoids, and investigate how much 
knowledge they possessed about these substances both chemically and their physiological 
effects. In addition, the present study investigated the relative perceived risks of using synthetic 
cannabinoids with regards to the deleterious physical and psychological effects that have been 
detailed in the literature.  
 This dissertation was organized into five different chapters. Chapter one provided an 
introduction, chapter two consisted of a comprehensive review of literature relevant to this topic, 
chapter three detailed the methodology of the present study, chapter four described the data and 
findings of the study, and chapter five included discussion and implications of the study based on 

















 Since 2008, synthetic cannabinoids have emerged as one of the more commonly used 
drug of abuse and then regressed in popularity to observed prevalence rates of less than 1%. 
While the majority of information on these drugs is surveyed from young adults, most research 
has found that this is also the most common population for use, making data repositories such as 
Monitoring the Future particularly important when making observations of synthetic cannabinoid 
use. However, since their emergence in 2008, limited research has been carried out to understand 
the drugs from an abuse standpoint. Further complicating these issues, the legal status and 
landscape of these substances has changed several times since their introduction which has had a 
notable impact on the presentation and use patterns of synthetic cannabinoids. Their structures 
have become increasingly complicated through the creation of not only novel compounds, but 
from the modification of existing compounds to skirt legal regulations as well as evade current 
drug detection methods.  
 The following chapter is structured in several sections to provide both an understanding 
of the mechanisms underlying synthetic cannabinoids that differentiate them from not only 
marijuana but also from other drugs of abuse as well as an overview of current literature relevant 
to the current study. Analysis is made of current literature surrounding the characterization of use 
of synthetic cannabinoids as well as their toxicity and association with the presentation of 
psychiatric symptoms and disorders. Overall research methodology relevant to the current study 
are discussed and critiqued to form the basis for the study at hand.  
Structure and Pharmacology of Synthetic Cannabinoids 




very misunderstood. The United nations Office on Drugs and Crime (2018) identified that to date 
there have been 251 different formulations of synthetic cannabinoids reported internationally, 
which represents the largest discrete drug category in terms of variety of substances reported. 
Synthetic cannabinoids can be grouped into five categories (Castellanos & Gralnik, 2016; 
Langford & Bolton, 2018): 
1) Classical cannabinoids, which have a structural relationship with Δ9-THC. 
2) Non-classical cannabinoids, which are based on derivatives of cyclohexylphenol. 
3) Hybrid-forms, which arise from combinations of classical and non-classical structures.  
4) Aminoalkyl indoles, which can be further subdivided into naphotoylindoles, 
phenylacetylindoles, naphtylmethylindoles, and benzoylindoles, are cannabinergic 
compound that can act as a cannabinoid receptor agonists.  
5) Endocannabinoids (eicosanoids), endogenous molecules involved in nervous system and 
immune system functioning.  
Starting in the late 1960s following the isolation of Δ9-THC, classical synthetic cannabinoids 
were the first to be derived and remained the only synthetic cannabinoids for nearly a decade 
(Law, Schier, Martin, Chang, & Wolkin, 2015; United Nations Office on Drug and Crime, 
2011). Classical cannabinoids are not often observed in recreational synthetic cannabinoid blends 
because of the difficulty and expense involved in their synthesis. Non-classical cannabinoids 
were developed in the late 1970s by Pfizer as potential analgesic compounds (Seely et al., 2012). 
The hallmark of these non-classical cannabinoids’ popularity in the market is the each in which 
they are synthesized and their retention of full antagonistic effect on CB1R receptors causing 
psychoactive effects similar to that of Δ9-THC. Hybrid forms have a combination of classical 




mimic the effects of Δ9-THC. They also represent the largest group of identified compounds and 
the easiest group to create more novel compounds through the addition of halogen, alkyl, alkoxy, 
or other substituents to one of the aromatic ring systems among other relatively simple 
alterations (United Nations Office on Drug and Crime, 2011). The Endocannabinoid class 
represents synthetic analogues of cannabinoids that are naturally occurring in the body (United 
Nations Office on Drug and Crime, 2011). Trade names of synthetic cannabinoids follow a 
relatively simple system of identification. They are represented by an alphanumeric code 
referencing the institution or individual who isolated them as well as their identification number 
(e.g. JWH-XXX – John W. Huffmann, HW-XXX – Hebrew University) (Debruyne & Le 
Boisselier, 2015).  
Characterization of Synthetic Cannabinoid Use in General Populations 
 To date, few studies have been carried out the characterize the use of synthetic 
cannabinoids relative to other drugs of abuse. Of these studies, even fewer extend beyond 
interpretation of large scale sampling sources such as the Monitoring the Future program or 
outside of niche populations like athletes, individuals engaged in treatment programs, or poly-
drug users. The most recent publication interpreting the Monitoring the Future data, Palamar and 
Acosta (2015), shown that 10.1% of high school seniors reported using synthetic cannabinoids in 
the last 12 months and 3.2% reported frequent use. Males reported using synthetic cannabinoids 
more than females and compared to white students, black students were at low odds for use. 
Though their analysis eliminated many contributing variables to use when controlling for other 
drugs use, a consistent correlate for use was how many evenings were spent out for fun. Lifetime 
alcohol use nearly doubled the odds that high school seniors would use synthetic cannabinoids, 




synthetic cannabinoids. Considering frequent use of synthetic cannabinoids, Palamar and Acosta 
(2015) found that males, students with higher levels of income, individuals who go out for fun 
more frequently, who have used alcohol, cigarettes, marijuana, or any other illicit drugs were 
more likely to use synthetic cannabinoids frequently.  
 Palamar and Acosta’s (2015) methodology involved analysis of a nationally 
representative study of high school students, surveyed yearly in over 100 schools, both public 
and private throughout the contiguous United States. Yearly, approximately 15,000 high school 
seniors are surveyed each year. Though all forms of this survey assess sociodemographic factors 
and use of various drugs, only forms concerning use over the past 12-month period have 
questions to assess synthetic cannabinoid use. Thus, while utilizing the most robust sample of 
young adult drug use, only about one third of the total sample are asked questions about 
synthetic drug use, representing an approximate n = 5,000. The Monitoring the Future project 
began asking about synthetic cannabinoid use starting in 2011, thus this sampling range 
represents aggregated data of the three most recent cohorts (2011 – 2013) at the time of 
publishing. While this seems to be the only large scale analysis of Monitoring the Future data as 
it relates to synthetic cannabinoid use, since 2013 prevalence of use has shifted notably to rates 
of less than 1%, representing a marked decline and potentially rendering the results of this 
investigation outdated and of limited current use.  
 Differing from the previous analysis, Caviness, Tzilos, Anserdon, and Stein (2015) 
sampled1080 individuals aged 18-25 to investigate predicting factories of synthetic cannabinoid 
use  in a community sample. Participants averaged 21.4 years old, were 53.4% male, and 58.9% 
non-Hispanic white. Nine point three percent of respondents reported using synthetic 




hallucinogens. 99% of respondents who reported using synthetic cannabinoids had used 
marijuana in the past and 62% reported daily use of marijuana. Consistent with other studies, 
males used synthetic cannabinoids more than females as well as a high rate of use among white 
respondents. Those not in college and in the workforce were also found to use synthetic 
cannabinoids compared to college engaged peers. Caviness et al. (2015) suggest that this is 
potentially a result of individuals motivated by avoidance of detection in drug screens 
implemented in the workforce. Individuals who used synthetic cannabinoids also had much 
riskier poly-drug use profiles when compared to non-synthetic cannabinoid using counterparts.  
 Caviness et al.’s (2015) data collection method utilized telephone interviews targeting 
individuals ages 18-25. Advertising on public transportation, college newspaper, and on public 
radio, the researchers invited interested persons to call the study phone number or send an email 
to the study address to recieve a return call to be screened. Individuals provided verbal informed 
consent, and provided their answers confidentially to a researcher during a 10-minute phone 
interview; respondents were queried about their recent use of alcohol and drugs, including 
synthetic cannabinoids. This collection method, over a 18-month period, proved effective and 
allowed the researchers to recruit 1080 participants within the defined age range for the purpose 
of this study.  
 Gunderson, Haughey, Ait-Daoud, Joshi, and Hart (2014) took a different approach to 
characterization of synthetic cannabinoid use. Their study stands alone as the only investigation 
into synthetic cannabinoid use by current marijuana users. Considering previously discussed 
studies, it was known and later corroborated that individuals who use synthetic cannabinoids 
have a very high likelihood of also having a history of marijuana use or concurrent use. 




Gunderson et al. (2014) from other studies, is that their analysis allows for estimation of the 
inverse of this metric, and an understanding of the prevalence of synthetic cannabinoid use 
among those already participating in an activity identified as a risk factor for synthetic 
cannabinoid use. While nearly all respondents were familiar with synthetic cannabinoids, 50% 
reported a history of synthetic cannabinoid use, and 24% reported current synthetic cannabinoid 
use. Gunderson et al. (2015) also investigated motivations for use among this population. 
Common reasons for use included seeking a new high similar to that of marijuana and avoiding 
detection via drug use screening methods (urinary analysis). Relevant to the current study, 
Gunderson et al. (2015) reported that respondents commonly experienced adverse effects as a 
result of synthetic cannabinoid use. These effects included difficulty with thinking clearly, 
headache, xerostomia, and anxiety. No individuals in this study reported experiences of paranoia 
or psychosis, which may be mediated by biologic vulnerability of the sample population.  
Several limiting factors are present for this analysis. Potential participants had to report 
regular cannabis use or tobacco use over 10 cigarettes per day, and consent to be contacted for 
future research after participation in a previous study. Utilizing telephone data collection 
methods similar to Caviness et al. (2015), the study at hand yielded N=42. Compared to other 
samples, this relatively small number of participants is a limiting factor in this analysis. Though 
it provides useful and unique data, it’s generalizability is limited due to low power and regional 
constraints of the participants. The target population, though, is also small and difficult to access 
causing studies of this nature with a large randomized sample to be particularly difficult. That 
being considered, data yielded from this study is particularly important considering the 
prevalence of marijuana among users of synthetic cannabinoid users in previous research. It is 




marijuana, potentially less than one quarter of frequent marijuana users also use synthetic 
cannabinoids representing a non-bi-directional relationship of use that might have been inferred 
from previous studies.  
Winstock and Barratt (2013) performed the most recent analysis characterizing synthetic 
cannabinoid use utilizing, to date of publication, the largest self-report sample of recent synthetic 
cannabinoid users describing their demographic and drug use characteristics. Utilizing online 
sampling methods, a total of 14,855 responses were received from global participants. 22.6% (n 
= 3362) were from the United States, approaching the number of respondents sampled in the 
Monitoring the Future data set analyzed by Palamar and Acosta (2015). 91.5% of participants in 
the global sample identified as white, with a median age of 26 and 70.6% of respondents were 
male. Of the global participants, 16.8% reported ever using synthetic cannabinoids. Of those 
respondents, 40.6% of them reported synthetic cannabinoid use in the previous month. Users of 
synthetic cannabinoids were generally male (79.6%), with a median age of 23 and a mean age of 
25.3. Two thirds of respondents reported that they were currently working, and over half 
reported being a current student.  
Among recent users of synthetic cannabinoids, the median age of first use was 21 years 
old. Of recent users, 39.4% reported use within the last 30 days. Of those participants, 32.6% 
reported only one use, 36.8% reported use on 5 or more occasions, and 4.8% reported daily use. 
99.3% of recent synthetic cannabinoid users reported a history of use of marijuana. Poly drug use 
was common, with most synthetic cannabinoid users reporting using alcohol, tobacco, and 
energy drinks within the last month. 36.2% of respondents were daily tobacco smokers and 
almost half of this sample reported using MDMA (ecstasy) in the past 12 months, and one third 




An important and unique component of Winstock and Barratt’s (2013) analysis was their 
attempt to compare user effects between synthetic cannabinoids and marijuana as well as an 
attempt to characterize why respondents may display a preference to synthetic cannabinoids over 
their natural counterpart. Marijuana was rated as having greater pleasurable effects during use 
and having greater sedating effects compared to synthetic cannabinoids. Interestingly though, 
respondents reported that they were more able to function normally after using marijuana 
compared to synthetic cannabinoids. Marijuana was reported to inflict more memory 
impairment, be more addictive, and produce a more consistent high than synthetic cannabinoids. 
Synthetic cannabinoids were reported though to be a better value cost wise when compared to 
marijuana. Synthetic cannabinoids were reported to produce more negative effects during use. 
Individuals that reported a preference for synthetic cannabinoids over marijuana (7.2%) were 
asked to identify the most important reason for their preference. The most important reason 
identified was their effect/high (58%), followed by synthetic cannabinoids availability (18.9%), 
then their ability to evade urine screening (14.5%), and last their cost (8.7%). 1.8% of 
respondents reported that they would like help/treatment to reduce or cease their use of synthetic 
cannabinoids. Some limitations were present in this study. In an attempt to maintain anonymity 
and prevent any potential for information tracking of respondents, no identifying information 
including IP addresses were retained. As a result of this, no protocol was in place to prevent 
multiple responses from single respondents. However, because no incentives were provided for 
participation in this study, it is unlikely that multiple responses would be a factor great enough to 
influence results in such a large sample. This study also relied on self-report data and 
participant’s proficiency in their self-history. Participants may have reported their previous use 




reported substance use screenings. This study represents one of the only large scale independent 
samplings of synthetic cannabinoid use and provides unique insight into both use patterns and 
demographics, as well as providing unique comparisons to marijuana use and validating online 
data collection methods for this population.  
Stogner and Miller (2014) collected data to profile synthetic cannabinoid users in a 
sample of 2,349 United States college students between 2011 and 2012. This time point is 
notable as it pre-dates the majority of legal actions taken to schedule and criminalize synthetic 
cannabinoids for recreational use. Classes at the university were randomly selected and all 
students were allowed to participate regardless of enrollment status; duplicate participants had 
their second submission thrown out (n = 202). The researchers specifically targeted all synthetic 
cannabinoid use and attempted to identify a wide variety of retail names commonly used for 
synthetic cannabinoids to avoid confusion or misidentification of substances in self-report.  
Of the students surveyed in this study, 14.3% reported lifetime use of synthetic 
cannabinoids with an average age of initiation of 18. Approximately 7.1% of respondents 
reported use of synthetic cannabinoids in the past year and 2.7% reported use in the previous 
month. Men were twice as likely to report lifetime use than women and almost twice as likely to 
report use in the past year. Lifetime use was also correlated with lower grade point averages. 
Lifetime use was also more prevalent in respondents with family incomes over $100,00 per year. 
Sexual orientation also was correlated with lifetime use of synthetic cannabinoids, with LGBT 
members reporting lifetime use of 26.6% versus 13.7% in heterosexual respondents. Notably, use 
of synthetic cannabinoids was low among those that abstained from alcohol use (0.3%) and 
among those that did not use marijuana (0.4%). Overall, Stogner & Miller (2014) found that 




most likely to use synthetic cannabinoids as well as those that use other substances.  
Stogner and Miller (2014) a detailed profile of synthetic cannabinoid use among young 
college students. Some limitations exist in this study, notably that the sample population is bound 
to individuals pursuing college education and may not be generalizable to the population of 
synthetic cannabinoid users as a whole. This study is one of few that investigated use patterns 
among LGBT individuals, however their analysis did not include comparisons of usage rates of 
other drugs between LGBT and heterosexual populations to investigate whether this is a 
phenomenon unique to synthetic cannabinoid use or a trend prevalent among multiple classes of 
substances. Corroborating other studies, synthetic cannabinoid users tend to use other substances 
with nearly all reported users also reporting use of tobacco, alcohol, or marijuana.  
Vandrey, Dunn, Fry, and Girling (2012) conducted an internet based survey to 
characterize use of synthetic cannabinoids, with all participants reporting at least one lifetime use 
of a synthetic cannabinoid product. Important to note, as with Stonger and Miller (2014), the 
time that this survey took place pre-dates the criminalization of synthetic cannabinoid products 
in the United States and may not be current or generalizable to extant populations as lifetime use 
has likely decreased as a function of adult population due to recent declines in prevalence among 
young adults. This study also has a relatively low number of participants (N = 168) and 
comprised an international sample representing 13 different countries, which also limits the 
generalizability of this data as the investigators did not articulate what percentage of participants 
were from the United States. This study, though, was unique in that is attempted to investigate 
where individuals who were using synthetic cannabinoids were acquiring them from.  
Similar to previously discussed studies, synthetic cannabinoids users were primarily male 




full time (46%) and one quarter being students (28%). Polydrug use was also common, with 92% 
of participants reporting alcohol use, 84% reporting marijuana use, and 66% reporting tobacco 
use. These numbers are in line with previous usage, however demographic data on prevalence of 
synthetic cannabinoid use among non-Caucasian groups was not presented. The majority of 
participants reported obtaining synthetic cannabinoids from gas stations and convenience stores 
(87%), from the internet (37%), and from friends and relatives (29%). Though 49% of 
participants reported living in an area where laws had been enacted restricting the sale of 
synthetic cannabinoids, only 2% of participants reported acquiring synthetic cannabinoids from 
an illicit drug dealer. This is of the limited evidence demonstrating that even with laws in place 
to curtail the sale of synthetic cannabinoids, these substances are often available through 
relatively accessible channels while still being illegal.  
Unlike other studies of this type, average age of first use was relatively high at 26, with a 
large amount of participants reporting regular synthetic cannabinoid use, with 55% reporting use 
in the past month and 39% reporting use in the past week. Though high compared to other 
studies, these numbers may accurately reflect the prevalence rate of synthetic substance use at 
the time of survey as in 2011, synthetic cannabinoids were the most commonly used illicit 
substance behind marijuana (Monitoring the Future, 2016). Vandrey et al. (2012) also 
investigated the subjective effects of synthetic cannabinoids among users. The most frequently 
reported positive effects were a pleasant high (37%) and increased appetite (14%), with the most 
frequently reported negatives effects being xerostomia (14%) and feeling lightheaded (13%).  
Considering the discussed literature that has attempted to characterize the use of synthetic 
cannabinoids, several consistent themes stand out that identify potential risk factors for use. 




or ever use of marijuana, tobacco use, alcohol use, and having a higher household income. A 
subset of the discussed studies purporting to characterize synthetic cannabinoid use also 
examined reasons why users may choose these substances over marijuana. The most commonly 
identified reasons are their particular high/effect, their availability, their cost when compared to 
marijuana, and the ability to bypass traditional drug screening methods used in various contexts. 
Generally, these studies utilize self-report methods via online or phone surveys. While 
susceptible to the limitations inherent to self-report survey research, the relative small size of the 
population as well as the legal concerns of disclosing use of these substances make the 
anonymity provided by online survey methods to be the preferable channel for data collection.  
Relevant to the current study, to date no investigation has been made into the large 
amount of former synthetic cannabinoid users as to why they have discontinued use of this drug 
class. Inferences can be made based on the changing legal landscape of these substances as well 
as the changing legal status of marijuana across the United States. However, acute poisonings as 
a result of synthetic cannabinoid use is increasing, representing a need for targeted intervention 
strategies that can be informed by increased understanding of not only risk factors but protective 
factors as well as motivation to discontinue use of these substances (Riederer at al., 2016). 
Synthetic Cannabinoid Use in Specific Populations 
 Several previously discussed studies identified that the overwhelming majority of 
individuals who use synthetic cannabinoids also use some other psychoactive substances, notably 
marijuana but also tobacco and alcohol. With this consideration in mind, Bonar, Ashrafioun, and 
Ilgen (2014) worked to further advance the characterization of synthetic cannabinoid use by 
investigating use among individuals participating in residential substance use disorder treatment. 




disorder (SUD) treatment program serving a large Midwestern United States population, Bonar 
et al. (2014) recruited 396 SUD treatment patients. The mean age was 34.8 years (SD=10.7) with 
67% male and 75% white participants. Of those surveyed, 38% (n=150) reported ever use of 
synthetic cannabinoids, with 79% (n=119) endorsed use within the past-year. Similar to other 
motivations for use, Bonar et al. (2014) found that 91% of participants tried synthetic 
cannabinoids out of curiosity/experimentation, 89% reported using synthetic cannabinoids for 
their high, 71% reported using synthetic cannabinoids for their relaxing effect, 71% also reported 
that their use was motivated by the ability to get high without having a positive drug screen. 
While the number of individuals reporting avoidance of drug screening in this study is relatively 
high, these results are understandable considering the context of substance use treatment that the 
study was performed in. It should also be noted that a potential client pool for this treatment 
facility came from the department of corrections, potentially influencing the number of 
individuals motivated to avoid positive drug screens.  
 Further analysis was performed to attempted to differentiate between those with lifetime 
synthetic cannabinoid use and those who did not use. Lifetime users were younger, more likely 
to be white, and were more likely to report polysubstance use. Participants who reported lifetime 
use of synthetic cannabinoids also reported more severe symptoms of depression, higher levels 
of general psychiatric distress, more likely to report paranoid ideation, and psychosis. This 
information is important in characterization studies as previously discussed, studies have 
identified a relationship between synthetic cannabinoid use and psychiatric symptoms (Fattore, 
2016; Fattore & Fratta, 2011; Cooper, 2016; Trecki et al., 2015; Debruyne & Le Boisselier, 
2015; Spaderma et al., 2013; Castellanos & Gralnik, 2015; Every-Palmer, 2010). Overall, 




two thirds reporting their motivation for use as avoidance of drug screening methods. Interesting, 
30% of participants with synthetic cannabinoid use endorsed that they felt it was safer than other 
drugs. Schulenberg et al.’s (2016) data investigated perceived risk of synthetic cannabinoids, but 
not perceived safety; this information represents valuable insight into why individuals may 
continue to use these substances.  
 Another specific population of individuals who may have incentives to utilize synthetic 
cannabinoids are military personnel. Berry-Caban, Kleinschmidt, Rao, and Jenkins (2012) 
investigated both synthetic cannabinoid use as well as synthetic cathinone use among United 
States soldiers. While not discussed in this paper, synthetic cathinones represent another group of 
synthetic drugs of abuse that are colloquially known as “bath salts”. The target population 
consisted of active duty soldiers that presented to a military emergency medical department and 
either endorsed substance use or were suspected by a provider to be using illicit substances 
(N=155). Of the sample, 7.7% (n=12) tested positive for synthetic cannabinoid use and 8.3% 
(n=13) tested positive for synthetic cathinone use. Rates of synthetic cannabinoid use were 
concentrated in individuals aged 19 to 24 (75%) consistent with other studies characterizing its 
use. Berry-Caban et al. (2012) did not do further investigation into the motivations for use of 
synthetic cannabinoids or cathinones in this investigation. 
 A similar study was performed by Heltsley et al. (2012) investigating the prevalence of 
synthetic cannabinoid use among athletes in the United States. Their methods involved using 
specific urinalysis of samples taken from participants for metabolites of the two synthetic 
cannabinoids JWH-018 and JWH-073. Analyzing samples from 5,946 athletes, Heltsey et al. 
detected metabolites of the two synthetic cannabinoids in 4.5% of the sample (n=266), with the 




in previously discussed studies, these numbers were notable as the authors articulated that 4.5% 
placed synthetic cannabinoids among the most detected drug class among all screened for in that 
particular laboratory. Limitations also were present in this study that may have limited the ability 
for the researchers to identify all potential cases of synthetic cannabinoid use, as JWH-018 and 
JWH-073 are two of hundreds of synthesized synthetic cannabinoids. However, this information 
is impactful as it places synthetic cannabinoids at the top of drug classes that are used by 
individuals who have incentive to avoid detection.  
Synthetic Cannabinoids and Psychosis 
 An emerging line of research that has emphasized the importance of understanding use 
patterns as well as the need for harm reduction strategies in synthetic cannabinoid use is its 
relationship with psychiatric symptoms and particularly psychosis. While the relationship is 
complicated, much like the relationship of marijuana use and psychosis, it’s frequency is being 
observed at a much higher rate in a much shorter period and has generated notable concern about 
the potential for future harm to users. At early as 2011, only three years into the widespread 
proliferation of synthetic cannabinoids in the United States, authors began analyzing case studies 
of psychosis presentations in synthetic cannabinoid users. Pierre (2011) was of the first to 
aggregate these case studies and examining psychosis associated with synthetic cannabinoid use 
in both individuals with a history of psychotic symptoms and those without. When evaluating 
individuals with psychosis related to synthetic cannabinoid use, Pierre (2011) observed a near 
50% split between those with a history of psychosis and those without any history. The majority 
of the studies identified JWH-018 as the suspected synthetic cannabinoid resulting in psychosis.  
In one case study discussed by Pierre (2011), though symptoms resolved in 70% of 




patients. While the relatively low number of observations (N=10) in this instance limits its 
generalizability, it still presents the alarming possibility that chronic psychotic symptoms may be 
triggered by synthetic cannabinoid use. When considered together, the initial reports investigated 
by Pierre (2011) suggested that acute psychosis in patients with no psychiatric history was 
associated with synthetic cannabinoid use as well as the potential for exacerbation or triggering 
of psychotic symptoms in previously stable individuals with a history of psychotic symptoms.  
 Fattore (2016) carried on the same thread of Pierre’s (2011) work continuing to interpret 
new case studies that have been presented to understand the relationship between synthetic 
cannabinoid use and psychosis. While there are no controlled clinical trials demonstrating the 
association to date, Fattore (2016) came to largely the same conclusion that Pierre (2011) did 5 
years earlier.  
Fattore (2016) generally concluded that: 
“Compelling evidence shows that SCs are able to trigger psychotic symptoms not only in 
vulnerable individuals, who re-experience psychosis after consumption, but also in 
subjects with no previous history of psychosis, who may experience prolonged psychotic 
episodes after smoking products containing SCs.” (p. 541) 
The literature on these associations is limited and most data are gathered from emergency 
department admissions as well as reports from poison control centers. Fattore (2016) also 
identified many of the issues that arise from relying on case studies for information on the 
association of synthetic cannabinoids and psychosis. Particularly that there is often no 
differentiation between new onset of psychosis and individuals with a history of psychosis. The 
majority of reports also do not disclose which specific compound was responsible for the 




accessibility. This is a major limitation in understanding of the association as the complexity of 
the emergence of new compounds as well as the modification of existing compounds through 
methods such as fluorination may impact the influence that these substances have on triggering 
psychiatric symptoms.  
 The most recent, complex, and thorough meta-analysis of current reports on the 
association of synthetic cannabinoid use and psychosis was performed by Deng, Verrico, Kosten 
and Nielsen (2018). Searching all available published literature that contained information on the 
association of synthetic cannabinoid use and psychosis, ultimately analyzing 42 articles. With 
regards to new-onset psychosis, Deng et al. (2018) identified studies discussing patients that had 
new-onset psychosis with both positive and negative psychiatric histories, as well as identifying 
onset of psychosis in individuals with strong genetic predisposition to mental illness. Deng et al. 
(2018) investigated relapse of psychosis instigated by synthetic cannabinoid use. While there are 
less cases of these documented in the literature, it should also be noted that there are instances in 
the literature of psychotic relapse in similar populations from multiple drugs of abuse. While this 
does not rule out synthetic cannabinoids as a potential for relapse in individuals with positive 
psychiatric histories, less emphasis has been placed on this line of research due to this being the 
norm rather than the exception when considering substance use disorders in psychiatric 
populations. 
 Deng et al. (2018) concluded that a causal effect in some instances of presentation of 
psychosis symptoms after use of synthetic cannabinoids is likely based on the literature but not 
conclusive. Recent studies analyzed also demonstrated that cohorts of synthetic cannabinoid 
users are more severely psychotic than marijuana using peers, including when controlling for 




concluding on a causal relationship is, as previously discussed, the majority of synthetic 
cannabinoid users also use other drugs. It is impossible to rule out the potential impact that these 
drugs have on the development of psychosis, though retrospective works have suggested that 
there are higher rates of psychosis in populations that use synthetic cannabinoids. Previous 
literature has established a dose dependent relationship between prior cannabis use and the 
development of schizophrenia, that relationship is unclear with synthetic cannabinoids.  
 Considering the relevant literature, development of psychosis is a ubiquitous concern 
when considering negative effects of synthetic cannabinoid use. Though there are other 
complications that may arise from use of these substances, both physiological and psychological, 
the association of psychotic symptoms and the potential for these symptoms to become chronic 
are a top concern. The novelty of these substances, their rapidly developing chemistry, as well as 
their rapid progression to Schedule I status in the United States has prevented the performance of 
a randomly controlled study to investigate the negative effects that these drugs may have on 
individuals enough to establish causal relationships. Researchers must continue to rely on case 
reports from medical treatment facilities as well as poison control centers’ data to build 
knowledge on the effects that these substances have.  
Summary of Research Findings 
 Synthetic cannabinoids are complex drugs that have several subtypes and complications 
such as fluorination making their classification difficult and understanding the effects of 
individual compounds nearly impossible. With an estimated prevalence rate of less than 1%, the 
user base of these substances are diverse but generally consist of young white males, who are 
poly drug users, and have a higher than average household income. Mixed motivations for use 




methods, availability of synthetic cannabinoids, their cost, and a preference for their mood 
altering effects when compared to other drugs. New onset psychotic symptoms as well as relapse 
of psychotic symptoms in individuals with history has been associated with synthetic 
cannabinoid use. Though the relationship is complicated and not well understood, it is clear that 
some interaction exists with synthetic cannabinoids that may instigate the presentation of 
psychosis in vulnerable individuals.  
Previous Research Methods 
 The majority of previous research methods to characterize the use of synthetic 
cannabinoids rely on self-report through either survey methods or live scripted interviews, with 
many participants being recruited or analyzed as a subset of a larger study aimed at substance use 
in general or at a different substance with a high level of co-occurring use. Due to the illegal 
nature of the use of synthetic cannabinoids as well as the current low levels of prevalence in the 
general population, the utilization of online survey based research to recruit from a large pool of 
potential participants seems appropriate when attempting to form a representative and 
generalizable sample population when compared to traditional survey sampling methods.  
 There is no consistent data collection method demonstrated in the relevant literature. Of 
the extant studies discussed, two relied on phone interviews to collect data, two relied on internet 
based surveys of international populations, one relied on a large government funded data 
collection program, and another sampled college students through in class participation 
incentives. Limitations exist in all of these methods of data collection that will attempt to be 
addressed in the present study. Telephone interviews, while having the ability to gain accurate 
survey information and curtail confusion originating from survey questions, is very labor 




while time and cost effective, present limitations with the global nature of the internet and 
limitations of who can participate to target a specific population. Online surveys can also be 
filled out inaccurately, rushed, or performed for monetary gain when incentives are involved. 
Sampling college students, while a convenient audience, limits the generalizability of substance 
use data as previous literature has shown that synthetic cannabinoid use is highly age correlated.  
 Data collected concerning the use of synthetic cannabinoids, outside of case studies on 
emergency department presentations, rely on self-report. Especially with consideration of 
estimation of use over long time periods, self-report may be inaccurate. It is difficult to 
accurately estimate and recall use frequency with a high level of acuity after an extended period. 
Self-report measures are also subject to many biases, such as social desirability, demand 
characteristics, and extreme responses. Social desirability bias, being of great concern for self-
report surveys surrounding substance use, has been observed to account for 10%-70% of the 
variance explained in participant responses (Nederhof, 1985). However, even when considering 
these factors, no alternative method superior to self-report was identified to collect data for this 
type of research. This conclusion is consistent with the the relevant literature surrounding 
synthetic cannabinoid use.  
 No extant measure exists that is validated specifically for use to understand and 
characterize the use of synthetic cannabinoids. The surveys and measures used in the previously 
discussed literature aimed at characterization of use were formed by content validation methods 
with consideration of the relevant research questions at hand. Because of the dichotomous nature 
of many of these variables, analytical methods often do not extend past simple inferential 
statistics and analyses of variance. The current study borrows from these methods, as they are 




primary recruitment source.  
Summary 
 At present, no known study to date has attempted to provide an explanation for the 
changes in prevalence of synthetic cannabinoid use. Though, with this decrease in use, data 
shows an increase in acute poisonings as well as other negative effects associated with the 
recreational use of these drugs. Literature exists on the structure and function of these substances 
as well as the psychotomimetic of these substances. Likewise, limited literature exists on the 
characterization of use of synthetic cannabinoids and provides insight into risk factors associated 
with synthetic cannabinoid use. Unfortunately, because of the dynamic legal landscape of these 
drugs as well as the growing diversity of these substances, much earlier research on use of these 
substances is outdated and not generalizable to the current population. Still, case studies and 
meta-analyses are being published examining the harmful effects of these drugs, and future 
directions are aimed at better understanding harm reduction methods specific for this drug class.  
 The current study was intended to be on the cutting edge of this research, forging a new 
paradigm in not only collecting information on the prevalence of use, but being the first to 
investigate motivating factors to discontinue use and add further knowledge to the 
characterization of use. Little is known about intervention methods for these drugs both 
medically and behaviorally. The current study was poised to fill that gap in the literature as well 
as continue collecting corroborating information to further confirm previous research findings to 









 The purpose of the study is to develop an understanding of why individuals with a history 
of synthetic cannabinoid use have decided to either discontinue use of these substances or 
continue use. First, I was interested in acquiring knowledge as to why individuals with a history 
of synthetic cannabinoid use have decided to discontinue use of these substances. Second, a goal 
was to investigate why individuals continue to use synthetic cannabinoids while examining the 
role of participant demographic information. Another factor investigated was related to synthetic 
cannabinoid users’ knowledge of the substances and what the perceived risks of synthetic 
cannabinoid use are. This chapter is a discussion of the methodology of the study in relation to 
the research questions, design of the study, sample, instruments, procedures, data collection and 
analysis, and limitations of the study.  
Sample 
 The sample (n = 297) was comprised of individuals from the online survey service 
Mechanical Turk who respond to the request to participate. Participants were limited to those 
residing in the United States who identify as having a history of use of synthetic cannabinoids. 
Participants were provided with informed consent through Qualtrics, an online survey platform 
often used in social sciences research, with a digital indication of consent. All participants were 
over the age of 18. Demographics of the sample are included in Table 1.  
Table 1. Age, Gender, Ethnicity, Race, Employment Status, Education, Synthetic Cannabinoid 
Use 
 
Demographic Characteristics Frequency (%) 
  
Age  
      18-24 41 (13.8%) 




      35-44 45 (15.5%) 
      45-54 46 (15.5%) 
      55-64 11 (3.7%) 
  
Gender  
      Male 163 (55.1%) 
      Female 129 (43.6%) 
      Non-binary/third gender 2 (0.7%) 
  
Ethnicity  
      Not Hispanic / Latino/a 234 (79.1%) 
      Mexican, Mexican American, Chicano/a 29 (9.8%) 
      Puerto Rican 11 (3.7%) 
      Cuban 4 (1.4%) 





      White/Caucasian 240 (81.1%) 
      Black or African American 22 (7.4%) 
      American Indian or Alaskan Native 5 (1.7%) 
      Asian 31 (10.5%) 
      Native Hawaiian or Pacific Islander 2 (0.7%) 
      Other 2 (0.7%) 
  
Employment Status  
      Employed 253 (85.5%) 
      Unemployed 22 (7.4%) 
      Student 16 (5.4%) 
  
Education  
      High School Education 35 (11.8%) 
      Some College 55 (18.6%) 
      Associate’s Degree 37 (12.5%) 
      Bachelor’s Degree 139 (47.0%0 
      Master’s Degree 25 (8.4%) 
      Professional Doctorate (MD, JD, etc) 2 (0.7%) 
      Doctorate (PhD, Ed.D, etc) 3 (1.0%) 
  
Synthetic Cannabinoid Use History  
      SC Use In Last 12 Months 148 (50.0%) 
      SC Use In Last 30 Days 70 (32.7%) 
  
Alcohol Use History  
      Alcohol Use in Last 12 Months 224 (75.7%) 





Tobacco Use History  
      Tobacco use in Last 12 Months 176 (59.5%) 
      Tobacco Use in Last 30 Days 153 (51.7%) 
  
Marijuana Use History  
      Marijuana Use in Last 12 Months 201 (67.9%) 
      Marijuana Use in Last 30 Days 165 (55.7%) 
  
Other Illicit Drug Use History  
      Other Drug Use in Last 12 Months 93 (32.1%) 
      Other Drug Use in Last 30 Days 73 (24.7%) 
  
  
Design of the Study 
 The study at hand utilized data obtained through the crowd sourcing participant 
recruitment platform Mechanical Turk in conjunction with cross sectional survey methods. 
Mechanical Turk (MTurk) is an online labor market that assists researchers with recruiting and 
compensating participants in a variety of research tasks. All participants affiliated with MTurk 
are assigned a set of qualifications that can be utilized by the researchers to limit who may 
participate in a study, such as country of residence or age. Researchers can also define custom 
qualifications for eligibility to participate in a study through MTurk. All surveys placed on 
MTurk are labeled as Human Intelligence Tasks or a HIT, which represents a single task that 
participants can respond to and be compensated for. By default, participants may only perform a 
HIT once and researchers are given the option to approve or deny a HIT, with participants only 
being compensated if a HIT is approved. It is possible to also limit participation to participants 
who have historically demonstrated that they fill out surveys accurately and have a notable level 
of performance exceeding regular users.  
This design allowed data to be collected from a sample to represent a larger population. 




observation of the behaviors of interest to the current study is simply not possible on a large-
scale basis through any other method. Online survey distribution methods have been chosen, as 
accessing the target population for the current study in a way that may be generalizable to the 
population is not possible through utilization of convenience sampling of university students. 
The utilization of online survey methods also allowed for a large amount of research participants 
to complete the survey in a short period of time.  
 MTurk is not without both advantages and limitations. In an analysis of papers evaluating 
the utility of MTurk in social sciences research, Cheung, Burns, Sinclair, and Sliter (2017) stated 
that data provided by MTurk participants had satisfactory psychometric properties as well as 
advantages in sampling participants from more diverse backgrounds. There were questions of the 
motive of participants who complete surveys and other tasks online for proportionately low 
compensation when compared to traditional wages. Representativeness was also a concern, with 
participants self-selecting themselves into online freelance work as a means of income. In studies 
utilizing the MTurk recruitment tool, participants tended to be younger, underemployed, more 
liberal, and less religious than the general population. There was also an overrepresentation of 
Whites and Asians. However, MTurk respondent pools are considered demographically more 
diverse than traditional student samples (Sheehan, 2018). In the context of the research questions 
in the study at hand, the benefits of having access to a nationwide sample with diverse ages 
outweighed the disadvantages summarized above.  
 Because of the economic motivation to complete surveys through MTurk, deception and 
misrepresentation may occur in order to qualify for a study. Sharpe-Wessling, Huber, and Netzer 
(2017) found that from 24% to 83% of participants passing screening questions are imposters 




However, there are steps that can be taken to minimize imposters from gaining eligibility to a 
study, such as disguising desired screening questions and answers and running a short, paid, pre-
screen. Online communities exist that provide information by those who have completed surveys 
to allow other users to bypass pre-screening questions to gain access to a survey to complete for 
financial gain thus revealing experimental conditions. However, these communities also serve as 
a safeguard against deception. In another study conducted by Sharpe-Wessling et al. (2017), 
findings revealed that compromising information that surfaced in online communities about their 
study was removed by moderating staff and only 3.8% of respondents were able to “guess” a 
random number, reinforcing norms that participants through MTurk are reliable respondents. 
Four research questions were developed to help guide the study. 
Research Questions 
1) What factors have motivated individuals to discontinue synthetic cannabinoid use? 
2) What factors contribute to the continued use of synthetic cannabinoids? 
3) What knowledge do individuals who currently use or have used synthetic cannabinoids 
possess on the physiological effects and known consequences of synthetic cannabinoid 
use? 
4) What are the perceived risks of using synthetic cannabinoids? 
There are two qualitative independent variables in this study: any history of use of synthetic 
cannabinoids and current use of synthetic cannabinoids. Information regarding these variables 
was collected from the screener questions at the beginning of the survey. These screener 
questions had the dual purpose of both collecting information on these variables as well as 
determining participant eligibility for the study. Dependent variables included the scores from 




discontinuation and continuation questionnaires are categorized as nominal variables, scores on 
the knowledge questionnaire are categorized as an ordinal variable,  and responses on the relative 
risk questionnaire are categorized as discrete variables.  
Instruments 
Discontinuation of Synthetic Cannabinoid Use Questionnaire  
The Discontinuation of Synthetic Cannabinoid Use Questionnaire is a 20 item self-report 
measure that obtains information related to the attitudes, opinions, and experiences that have 
influenced the respondent to discontinue use of synthetic cannabinoids or considering 
discontinuing the use of synthetic cannabinoids. Previous literature regarding this concept was 
reviewed and questions were developed to encompass previously assessed domains as well as 
novel reasons that have potentially not yet been evaluated in research. These domains encompass 
personal experiences, second-hand experiences, influence of information sources, preference 
towards other substances, risks to physical and mental health, accessibility, and concerns about 
the content of synthetic cannabinoid containing drugs. All items in this instrument were 
comprised of yes/no questions. Due to the exploratory nature of the study and this instrument, 
convergent and discriminant validity was not investigated because there were no extant 
instruments available to make comparisons with. Also, this unidimensional approach was taken 
to attempt to begin identifying discrete categories which may influence decision making as no 
theoretical framework yet exists for more complex instrument design. Items on the 
discontinuation questionnaire were also validated through consultation with other experts in the 
field of substance use disorders. Specifically, three additional individuals with doctorates in 
Rehabilitation Counseling having both extensive research design experience as well as expertise 




questions were appraised until the experts converged on the suitability of the remaining items for 
the purposes of this study. The discontinuation questionnaire was administered to all participants 
endorsing a history of synthetic cannabinoid use as it encompassed both reasons for 
discontinuation as well as future considerations to engender opinions of both current and 
previous synthetic cannabinoid users. This questionnaire was found to have an acceptable level 
of internal consistency with a Cronbach’s Alpha of .784. 
Continuation of Synthetic Cannabinoid Use Questionnaire  
The Continuation of Synthetic Cannabinoid Use Questionnaire is a 10 item self-report 
measure that obtained information related to the attitudes, opinions, and that have influenced the 
participant to continue using synthetic cannabinoids, use them in the past, or consider starting to 
use synthetic cannabinoids again. Previous literature regarding this concept was reviewed and 
questions were developed to encompass previously identified domains of interest as well as 
novel reasons that have potentially not yet been evaluated in research. These domains encompass 
drug screening, personal experiences, accessibility, legal concerns, and comparisons to other 
substances. Question format justification as well as content validation through expert 
consultation was identical to that of the discontinuation questionnaire. The continuation 
questionnaire was administered to all participants endorsing a history of synthetic cannabinoid 
use as well as current synthetic cannabinoid use as is encompasses both motivating factors for 
current use as well as motivating factors to begin using synthetic cannabinoids again after a 
period of abstinence. This questionnaire was found to have an acceptable level of internal 
consistency with a Cronbach’s Alpha of .782.  
Synthetic Cannabinoid Knowledge Questionnaire 




possess about synthetic cannabinoids. No known previous literature has assessed the 
understanding of synthetic cannabinoids and their associated side effects by individuals with a 
history of using these substances. The contents of this instrument were constructed with 
consideration of identified side effects/risks of synthetic cannabinoid use, common 
misconceptions of synthetic cannabinoids identified in the literature, identified issues in 
detection/screening methods through urinary analysis, and pharmacological effects. Individual 
items were also influenced by consultation with experts in the field of substance use disorders. 
The knowledge questionnaire was administered to all participants.  
Synthetic Cannabinoid Risk Comparison Index 
This instrument utilized Likert scale responses to characterize participants perceived 
danger of various drug classes of abuse, including synthetic cannabinoids. Rating items from 1 to 
10, with 1 being “Not Dangerous at All” and 10 being “Extremely Dangerous”. Comparisons can 
be made of the perception of danger of synthetic cannabinoids by comparison to other drugs. 
Utilization of data transformation methods allow this instrument to make relative risk 
comparisons between synthetic cannabinoids and other substance classes while controlling for 
baseline differences in overall perception of substance use risk between participants. The 
substance classes represented in this questionnaire were intended to create a comprehensive 
listing of commonly abused substances mimicking substances represented in Monitoring the 
Future survey data. The identical professional panel that assisted in content validation of 
previously discussed instruments also reviewed this category list and offered suggestions and 
inclusions. The Risk Comparison Index was administered to all participants.  
Data Collection Procedure 




Committee at Southern Illinois University Carbondale. Several steps are taken to maintain the 
anonymity of participants. Inherently, as a component of the MTurk system, Amazon had the 
ability to link responses on survey items to the participants’ identities if the study used Amazon’s 
data collection tools. To prevent the ability to match responses with identities, MTurk was only 
utilized for participant recruitment and remuneration for participation. Participants were 
redirected to survey materials through Qualtrics where no identifying information was collected. 
Upon completion of the survey, participants were given a randomly generated code number that 
they entered in the MTurk system to confirm that they successfully completed the survey without 
allowing MTurk administrators access to responses. Once confirmation of successful completion 
of the survey was made by the researcher and the participant was compensated, participants were 
assigned a code number de-identifying any potential association with their MTurk profile and 
maintained the anonymity of provided data. Along with responses to questions listed in the 
survey found in the index of this proposal, demographic information including age, gender, 
ethnicity, level of education, and employment status was collected.  
Data Analyses 
 All data were collected and analyzed in an ethical manner in accordance with the 
guidelines established by the Southern Illinois University Carbondale Human Subjects 
Committee. All data was kept in an appropriate and secured location in order to maintain 
confidentiality for all involved research participants. Descriptive, inferential, and multivariate 
statistics were used to organize, analyze, and evaluate the data.  
 Prior to data analysis, for the purpose of making inferences about the collected data, 
Exploratory Factor Analyses (EFA) were performed on the continuation survey, discontinuation 




structure of a set of interrelated variables without imposing a preconceived structure on the 
outcome (Child, 1990). Specifically, the EFA allows the researcher to determine the number of 
latent constructs underlying a set of items and quantify the dimensionality of this item set. This 
analysis was used in lieu of a Confirmatory Factor Analysis as this type of analysis is suited for 
subsequent validation studies of measures after their initial development. These analyses were 
performed to evaluate the dimensionality of the surveys based on participants’ responding and to 
evaluate internal consistency of survey items. Though these questionnaires will require continued 
validation to be appropriate for further utilization in research, for the purpose of this exploratory 
study, acceptable values of Cronbach’s Alpha and acceptable inflection points on scree plots 
were utilized to determine their suitability for this study.  
1) What factors have motivated individuals to discontinue synthetic cannabinoid use? 
2) What factors contribute to the continued use of synthetic cannabinoids? 
To answer research questions 1 and 2, individual questions were first analyzed using descriptive 
statistics. Z-Tests were then performed to determine significant differences in the proportion of 
respondents endorsing specific motivating factors to discontinue synthetic cannabinoid use and 
specific motivating factors to continue synthetic cannabinoid use. Following these initial Z-
Tests, Chi-Squared tests of independence were conducted comparing responses from participants 
who identified as current users of synthetic cannabinoids (use within the previous 30 days) and 
those who identify as historic users (lifetime history of use but not within previous 30 days). Chi-
Squared tests were chosen over Z-Test scores as this analysis allowed for interpretation of not 
only significant differences between motivating factors but also interpretation of significant 
differences in motivating factors between current and historical users of synthetic cannabinoids. 




individual questions for the Chi Squared analysis identify motivating factors that differ 
significantly between these two groups and signify a potential factor that can be addressed to 
understand underlying motivations. This methodology was chosen over Z-Tests as it allowed for 
inferences to be made about not only the significance of motivating factors, but also make 
comparisons between current and historical synthetic cannabinoid users.  
3) What knowledge do individuals who currently use or have used synthetic cannabinoids 
possess on the physiological effects and known consequences of synthetic cannabinoid 
use? 
To answer research question 3, data were analyzed using descriptive statistics to represent 
knowledge content of the participants. Participants’ correct responses on knowledge 
questionnaire items were coded as 1 and incorrect responses were coded as 0. This coding 
resulted in a final score for each participant representing their total correct responses to the 
knowledge questionnaire. A one-way Analysis of Variance (ANOVA) was performed to 
compare overall scores of individuals who identify as current users of synthetic cannabinoids and 
those who identify as historic users. A one-way ANOVA was chosen due to the structure of the 
data from this question; specifically, the dependent variables being categorical in nature and the 
single independent variable being ordinal. Significant results on this analysis suggested that there 
are notable differences in knowledge of synthetic cannabinoids between current users and those 
with a history of use and suggest the suitability of psychoeducation as a harm reduction strategy.  
4) What are the perceived risks of using synthetic cannabinoids? 
To answer research question 4, data was first transformed by utilizing each participant’s 
rating of the danger of synthetic cannabinoids as a baseline value and subtracting this number 




substance for each participant. These values were then averaged across the entire sample for each 
substance class. Each participant’s responses comprise individual differences in risk perception 
of drugs suggest that simple comparisons of risk ratings would likely yield data with little utility 
without transformation. Utilizing each participant’s rating of the danger of synthetic 
cannabinoids as a baseline value, this number was subtracted from their danger ratings from all 
other substances, creating relative risk ratings for each substance for each participant. These 
values were then analyzed using descriptive statistics to represent the sample’s overall relative 
risk rating of various substances to synthetic cannabinoids. Further statistical analysis is not 
necessary for the interpretation of data utilized to investigate this question, as quantifying 



















 Prior to any analysis being conducted, factor analyses were performed to determine the 
dimensionality of the scales utilized for this study as well as investigate potential redundancy in 
scale items. A factor analysis was run on the 20-question cessation of synthetic cannabinoid use 
scale and the 10-question continuation of synthetic cannabinoid use scale. There are several 
assumptions that must be met to perform an exploratory factor analysis. Variables should be 
metric in an exploratory factor analysis which is met in all cases. The sample size should be 
greater which is met in all three cases. The sample should also be homogenous. Reliability 
analyses were conducted on all three scales and their levels fells within acceptable limits; these 
are reported with the results from each respective factor analysis. Correlations of .3 are required 
between research variables, as well there should be no outliers within the data.  
Factor Analysis Results 
Discontinuation of Synthetic Cannabinoid Use Questionnaire Factor Analysis Results 
 An Exploratory Factor Analysis (EFA) was run on a 20-question questionnaire that 
measured attitudes towards cessation of use of synthetic cannabinoids. The suitability of EFA 
was assessed prior to analysis of 285 reported cases. The scale had an acceptable level of internal 
consistency, as determined by a Cronbach’s Alpha of .784. The overall Kaiser-Meyer-Olkin 
(KMO) measure was 0.802 with individual KMO measures all greater than 0.7, classifications of 
'middling' to 'meritorious' according to Kaiser (1974). Bartlett's test of sphericity was statistically 
significant (p < .05), indicating that the data was likely factorizable. 
 EFA revealed six factors that had Eigenvalues greater than 1 and which explained 




inspection of the scree plot indicated that one component should be retained (Cattell, 1966). In 
addition, a one-component solution met the interpretability criterion. As such, one component 
was retained.  
 A one-component solution explained 22.371% of the total variance. Though a six-factor 
analysis cumulatively explained more variance, identified factors 2 through 6 possessed 
Eigenvalues close to 1. Though this is over the threshold necessary for inclusion as components 
in the factor analysis, they are difficult to distinguish from factors 7 through 19 that were 
rejected for being below the threshold of 1 by the same absolute value. Thus, interpretation of the 
Scree Plot was necessary to determine the number of factors that should be retained. A scree plot 
is a plot of the total variance explained by each component via its Eigenvalue against other 
components. It should be noted that in the scree plot there are as many components as there are 
variables. Components that should be retained are those before the last inflection point of the 
graph, which is a point that represents when the graph begins to level out and subsequent 
components add little to the total variance. In this analysis, visual inspection of the scree plot 
indicated that one component should be retained (Cattell, 1966).  
 The one-component solution explained 22.371% of the total variance. A Varimax 
orthogonal rotation was employed to aid interpretability. The rotated solution, even when 
limiting extracted factors, failed to exhibit 'simple structure' (Thurstone, 1947) until limited to an 
extraction of one factor. The interpretation of the data was consistent with the attributes of the 
questionnaire designed to look at the single dimension of motivations to discontinue using 
synthetic cannabinoids with the strongest loading of items on component 1.  
Continuation of Synthetic Cannabinoid Use Questionnaire Factor Analysis Results 




measured attitudes towards continuation of use of synthetic cannabinoids. The suitability of EFA 
was assessed prior to analysis of 285 reported cases. The scale had an acceptable level of internal 
consistency, as determined by a Cronbach’s Alpha of .782. The overall Kaiser-Meyer-Olkin 
(KMO) measure was 0.843 with individual KMO measures all greater than 0.7, classifications of 
'middling' to 'meritorious' according to Kaiser (1974). Bartlett's test of sphericity was statistically 
significant (p < .05), indicating that the data was likely factorizable. 
 EFA revealed two factors that had Eigenvalues greater than 1 and which explained 
35.547% and 12.253% of the total variance, respectively. Visual inspection of the scree plot 
indicated that one component should be retained (Cattell, 1966). In addition, a one-component 
solution met the interpretability criterion. As such, one component was retained.  
 A one-component solution explained 34.547% of the total variance. Though a two-factor 
analysis cumulatively explained more variance, identified factors 2 through 4 possessed 
Eigenvalues close to 1. Though this is over the threshold necessary for inclusion as components 
in the factor analysis, they are difficult to distinguish from factors 3 and 4 that were rejected for 
being below the threshold of 1 by the same absolute value. Thus, interpretation of the Scree Plot 
was necessary to determine the number of factors that should be retained. In this analysis, visual 
inspection of the scree plot indicated that one component should be retained (Cattell, 1966).  
 The one-component solution explained 34.547% of the total variance. A Varimax 
orthogonal rotation was employed to aid interpretability. The rotated solution failed to exhibit 
'simple structure' (Thurstone, 1947) until limited to an extraction of one factor. The interpretation 
of the data was consistent with the attributes of the questionnaire designed to look at the single 
dimension of motivations to continue using synthetic cannabinoids with the strongest loading of 




After the Exploratory Factor Analyses were run on these two measures, it was determined 
that their internal consistency was adequate and that improvements to internal consistency and 
component structure would be marginally improved by removal of items from the instruments. 
This indicates that though some questions on the measures at face value seem similar, they are 
divergent enough from other items that they should be retained when making inferences about 
the research questions in the study at hand.  
Research Question 1 Results 
 What attitudes or opinions have motivated individuals to discontinue synthetic 
cannabinoid use? The purpose of this question is to explore what factors contribute to individual 
decision making leading to cessation of use of synthetic cannabinoids. After the factor analysis 
had been performed, Chi-Squared tests of independence were used to compare motivating factors 
between individuals who reported current use of synthetic cannabinoids and those who reported 
historical use of synthetic cannabinoids. Chi-square tests of independence have three 
assumptions that must be met: 1) There must be two variables that are measured at the 
categorical level, 2) There must be independence of observations, 3) All cell counts should have 
expected frequency measures greater than five.  
 A chi-square test for association was conducted between current synthetic cannabinoid 
use and all discontinuation questionnaire items. All expected cell frequencies were greater than 
five. All statistically significant associations between current use and discontinuation 








Chi Squared Tests of Association 
Discontinuing Use Items  χ2(1) p φ p 
I would rather use other drugs 12.177 .000 0.203 .000 
K2/Spice is difficult to obtain 6.401 .011 0.148 .000 
I’m unsure what K2/Spice does to my body 6.291 .012 -0.146 .000 
I didn’t/don’t enjoy using K2/Spice 12.655 .000 -0.207 .000 
I don’t know where K2/Spice comes from 11.690 .001 -0.199 .000 
I don’t know what K2/Spice actually is 4.436 .035 -0.123 .000 
 
Research Question 2 Results 
 What attitudes or opinions contribute to the continued use of synthetic cannabinoids? 
The purpose of this questions is to explore what motivations contribute to individual decision 
making leading to continuing to use synthetic cannabinoids. A chi-square test for association was 
conducted between current synthetic cannabinoid use and all discontinuation questionnaire 
items. All expected cell frequencies were greater than five. All statistically significant 
associations between current use and discontinuation motivations are listed below along with 










Chi Squared Tests of Association 
Continued Use Items  χ2(1) p φ p 
K2/Spice isn’t detected in drug screening tests 14.207 .000 0.219 .000 
I enjoy using K2/Spice 59.184 .000 0.449 .000 
K2Spice is safer than other drugs or alcohol 48.303 .000 0.406 .000 
My Friends Enjoy using K2/Spice 44.517 .000 0.389 .000 
K2/Spice is affordable to me 22.951 .000 0.279 .000 
K2/Spice is easy to obtain 17.464 .000 0.243 .000 
K2/Spice is legal 16.063 .000 0.234 .000 
I trust where K2/Spice comes from 57.911 .000 0.443 .000 
I trust that K2/Spice is pure 38.466 .000 0.362 .000 
K2/Spice is stronger than marijuana 6.565 .010 0.149 .010 
 
Research Question 3 Results 
What knowledge do individuals who currently use or have used synthetic cannabinoids 
possess on the physiological effects and known consequences of synthetic cannabinoid use?  
The purpose of this question is to investigate the general knowledge about synthetic 
cannabinoids among current and historical users of the substance. Scores were computed for 
each participant based on percentage of correct responses to the knowledge questionnaire items. 
Item 7 (K2/Spice is detectable in drug tests/urine screens) was not considered for this analysis as 
it cannot be accurately answered as a true/false question. This decision was made during data 




available detection assays, thus the answer is ambiguous.  
A one-way ANOVA was conducted to determine if general knowledge about synthetic 
cannabinoids was different between individuals who reported current use of synthetic 
cannabinoids and those with only historical lifetime use of the substance. Participants were 
classified into two groups: current use (n = 67) and historical use (n = 220). There were no 
outliers, as assessed by boxplot. Data was normally distributed for each group, as assessed by 
examining a histogram of the total score and obtaining kurtosis and skewness values. A 
conservative range of kurtosis and skewness values fall within a +1 to -1 range (Howell, 2009). 
The reported values (kurtosis = -.680, -.774; skewness = .429, -.619) fell within the conservative 
category range. The central limit theorem supports the assumption that groups with 20-30 
participants will meet the normality assumption (Howell, 2009). There was homogeneity of 
variances, as assessed by Levene’s Test of Equality of Error Variance (F(1, 285) = 1.706, p = .193). 
A result greater than .05 implies that the error variance in the conditions are not significantly 
different. Knowledge scores were significantly different between individuals who reported 
current synthetic cannabinoid use and those who reported only historical use (F(1,285) = 90.504, 
p = .000). Individuals who reported currently using synthetic cannabinoids had significantly less 
knowledge about the substance than those who did not report current use.  
Research Question 4 Results 
 What are the perceived risks of using synthetic cannabinoids relative to other 
substances? The purpose of this question is to understand how dangerous participants feel that 
synthetic cannabinoids are by comparing them to how they rank the dangers of other drugs. To 
answer this question, data transformations were made to make meaningful interpretation of the 




14 different substances on a Likert scale from 0 -10, with 0 being not dangerous at all and 10 
being the most dangerous. Variables were computed for each substance class by subtracting the 
score assigned to Synthetic Cannabinoids from the score assigned to each other drug class. These 
values were then averaged. Positive numbers represent perception of a substance as more 
dangerous than synthetic cannabinoids, and negative numbers represent perception of a 
substance as less dangerous than synthetic cannabinoids.  Average values for all substance 





















Relative Risk Comparison Data 
Substance Class Average Danger Rating Difference from SC Total Responses (n) 
Synthetic 
Cannabinoids 
6.6294 * 286 
Tobacco 6.5171 -0.1303 284 
Alcohol 6.4399 -0.1555 283 
Marijuana 3.1254 -3.5054 279 
Inhalants 6.7057 0.1309 275 
LSD 5.6272 -0.9596 272 
PCP 7.1697 0.5827 266 
Ecstasy 5.9386 -0.6593 276 
Bath Salts 7.2288 0.6180 267 
Cocaine 6.8648 0.1709 275 
Crack 7.3794 0.7309 275 
Heroin 7.9894 1.3297 276 
Methamphetamine 7.6547 1.0696 273 











The purpose of the current study is to expand existing research on the characterization of 
synthetic substance use, perceived harm of synthetic cannabinoids, and users’ knowledge about 
synthetic cannabinoids. Particularly, the study investigated specific contributing factors that led 
to the decision to quit or continue using synthetic cannabinoids. The study also investigated the 
knowledge about synthetic cannabinoids possessed by individuals with a history of use as well as 
relative perceived risk of synthetic cannabinoids. The previous chapter reflected the findings for 
the data analysis conducted on each reach question. In this chapter, I focused on discussion of the 
research findings and how these findings related to previous research, the implications of these 
findings, and the limitations of this study.  
Factor Analysis Conclusions 
Exploratory Factor Analyses (EFA) were run on both measures of motivations to continue using 
synthetic cannabinoids and motivations to discontinue using synthetic cannabinoids. For 
exploratory research, these analyses yielded favorable results suggesting acceptable internal 
consistency and dimensionality. While acceptable for the performed study, results should still be 
interpreted with caution until continued development and validation of these measures has been 
performed to further assess their validity, reliability, and utility.  
Research Question 1 Conclusions 
What attitudes or opinions have motivated individuals to discontinue synthetic cannabinoid use? 
 Several significant differences in motivating factors were found for the continuation of 
use between current and historical users of synthetic cannabinoids. Considering simple Z-Test 




considered through Chi-Squared tests between current and historical users, the results become 
much more interesting in the context of harm-reduction and intervention effectiveness. Access to 
synthetic cannabinoids was a notable factor, with current users being less likely to report 
difficulty in obtaining the substance. Preference and personal experience was also a significant 
factor, with historical users being significantly more likely to express preference for using other 
substances as well as negative personal experiences with synthetic cannabinoids as a reason they 
chose to no longer use the drug. Knowledge of the substance class, its effects on the body, and 
the source of the drug(s) were the remaining significant factors found in the analysis. Individuals 
with historical use were more likely to report concerns about the production of and physiological 
effects of synthetic cannabinoids than current users. Finally, knowledge about the nature of 
synthetic cannabinoids was a significant factor, with current users less likely to report concerns 
about what synthetic cannabinoids inherently are as a reason to discontinue use.  
 Though no study to date was found that explicitly investigated reasons that individuals 
discontinue use, Gunderson et al. (2015) reported that adverse effects related to synthetic 
cannabinoid use were common. Winstock and Barratt’s (2013) analysis also yielded consistent 
results with the current study, identifying that availability of synthetic cannabinoids is a notable 
consideration when making decisions to use these substances.  
Research Question 2 Conclusions 
What attitudes or opinions contribute to the continued use of synthetic cannabinoids? 
 Compared to considerations made for discontinuation, more significant factors related to 
decision making around continued use were identified. These results were somewhat expected, 
considering that many individuals who use synthetic cannabinoids are polydrug users (Vandrey, 




cannabinoids over other substances. Also, considering Monitoring the Future (2016) data, use 
prevalence has decreased at a high enough rate to suggest that discontinuation of use for most 
individuals is automatic or related to factors outside the scope of the current study. As with the 
first research question, examinations of significant differences in responding through simple Z-
Tests of the entire population did yield interpretable results, however with the goal of 
understanding motivating factors related to use, Chi-Squared analyses between current and 
historical users yielded more practical data for analysis.  
Consistent with previous studies, (Bonar et al., 2014, Vandrey et al., 2012), avoidance of 
drug screening methods was a significant factor considered when making the decision to use 
synthetic cannabinoids. Access was also a significant factor considered when making the 
decision to use, encompassing both affordability and availability as significant factors. 
Proportionately inverse to data collection in the discontinuation survey, positive personal 
experiences were the strongest significant factor for consideration to continue using. Participants 
also reported significant considerations on the perception that synthetic cannabinoids are safer 
than other substances, as well as a trust for the source and purity of the synthetic cannabinoids 
they are using.  
While not necessarily surprising, these results can be sorted into several smaller discrete 
categories for consideration of major motivating factors: access, safety, and experiences. Items 
falling in the safety category, such as trusting the purity and source of the synthetic cannabinoids 
had critical values second only to personal experience. Importantly, these topics can be 
addressed through psychoeducational materials and targeted specifically for intervention and 
harm reduction campaigns. Future publications intended for harm reduction should potentially 




concise information on the effects of these substances especially with comparisons to marijuana, 
and information about the production sources, purity, and differences between the discrete 
formulations of synthetic cannabinoids that are distributed under ubiquitous trade names such as 
K2 and Spice.  
Research Question 3 Conclusions 
What knowledge do individuals who currently use or have used synthetic cannabinoids 
possess on the physiological effects and known consequences of synthetic cannabinoid use?  
Though the study at hand intended to primarily investigate motivating factors that lead to 
decisions surrounding synthetic cannabinoids use, research question three was intended to look 
at the general knowledge possessed about synthetic cannabinoids by individuals with a history of 
their use. While originally intended to collect information about the sample population as a 
whole, characteristics of the sample population allowed multivariate statistical methods to be 
utilized to make comparisons in knowledge content between individuals reporting current use of 
synthetic cannabinoids and those with a history of use. To date, no known study of this type has 
been performed with which to make data comparisons.  
Though the overall results are not necessarily surprising, the spread in knowledge 
questions answered correctly on average between the two groups was unexpectedly large. 
Individuals who reported a history of use but no current use answered 74% (s = 24%) of 
questions correctly on average. Individuals who reported current use of synthetic cannabinoids 
answered 42% (s = 28%) of the knowledge survey questions correctly on average. This 
represents a difference of 32% in average scores on the knowledge survey. While this 
information should be interpreted with caution as this survey was exploratory in nature and has 




usability of this information. These results suggest that not only do individuals currently using 
synthetic cannabinoids have statistically significantly less knowledge about the substance class, 
the gap in knowledge is quite large.  
These results, when taken together with the results of research questions 1 and 2, suggest 
that psychoeducational campaigns may be particularly effective for harm reduction methods for 
this substance class. As explored in chapter 2, these drugs are exceptionally complicated when 
compared to more common substances and still complicated with regards to other designer and 
synthetic drugs. Additional complexity was introduced as a result of the rapid and fragmented 
legislative response to this drug class. These results suggest that consolidation of this type of 
information in accessible format and language may lead to increased cessation rates of synthetic 
cannabinoids.  
Research Question 4 Conclusions 
What are the perceived risks of using synthetic cannabinoids relative to other 
substances? 
The purpose of this question was to investigate participant’s perceived danger of 
synthetic cannabinoids relative to the perceived danger of other various substance classes. While 
multivariate analysis was not indicated for this research question, results were interesting. 
Participants rated Tobacco, Alcohol, Marijuana, LSD, Ecstasy, and Benzodiazepines as safer on 
average than synthetic cannabinoids. However, it should be noted that many of the differences 
were very small and caution must be taken when interpreting these results as strong conclusions 
cannot be drawn. Unsurprisingly, participants rated Marijuana as the least dangerous drug class 
of all those included on the list. This result is likely influenced by data suggesting that between 




(Vandrey et al., 2012;Winstock & Barratt, 2013). 
Participants rated Inhalants, PCP, Bath Salts (synthetic cathinones), Cocaine, Crack, 
Heroin, and Methamphetamine as more dangerous than synthetic cannabinoids. However, the 
risk on many substances was marginal, with Heroin and Methamphetamine as the only 
substances with an average risk difference of more than one point on the scale. Additional 
analysis outside the scope of this study is necessary to draw any meaningful conclusions from 
this data set beyond reporting of average values.  
Summary of Findings 
The primary purpose of this study was to explore motivating factors for continuation and 
discontinuation of synthetic cannabinoid use, with ancillary goals of understanding more about 
the general knowledge that users have about this substance class and their perception of its 
dangers. Participants reported that a preference to other drugs, difficulty to access, poor personal 
experience, and lack of knowledge on the source and physiological effects of synthetic 
cannabinoids were all reasons they consider quitting using this drug. Participants reported that 
avoiding drug detection screens, personal and collegial enjoyment, assumed safety, ease of 
access, and trust on the purity of synthetic cannabinoids were reasons they choose to continue 
using these drugs.  
Considering the differences in knowledge of current users and historical users, the study 
found that individuals who report current synthetic cannabinoid use have significantly less 
overall knowledge about the substance class than those who report only a history of use 
(F(1,285) = 90.504, p = .000). Participants rated Tobacco, Alcohol, Marijuana, LSD, Ecstasy, 
and Benzodiazepines as less dangerous than synthetic cannabinoids on average. Participants 




Methamphetamine as more dangerous than synthetic cannabinoids on average. 
Limitations and Delimitations 
 The present study was quantitative in nature but limited to non-experimental comparative 
design with analysis of data using Chi-Squared tests of independence and ANOVA. From the 
survey data, relationships between variables were be shown however no direct causation could 
be inferred. Another limitation of the present study emerges in regards to participant recruitment. 
Survey participants were recruited utilizing the online crowd sourcing data platform Mechanical 
Turk (MTurk) and compensated for their participation. It is possible that individuals participating 
in these surveys responded inaccurately to items, failed to utilize sufficient time to understand 
responses, or fabricated responses to questions pertaining to eligibility criteria to be remunerated 
for survey responses among other issues with online data collection. MTurk and the Qualtrics 
survey design system have tools available such as attention checks and reported time to 
completion of survey responses, as well as control over remuneration dispersion being given to 
the researcher to prevent misuse of the system. The method selected for this study, however, was 
the utilization of a screening “quiz” comprised of questions that individuals with a history of 
synthetic cannabinoid use should know. For example, asking if the substance needs to be kept in 
the freezer to remain viable. While this method is not without flaw, in the current study it 
rejected almost 50% of survey attempts. The quiz was sensitive to both correct answers as well 
as clicking one response through all of the options to speed through the questionnaire. While it 
cannot be guaranteed that no participants attempting to misrepresent themselves to gain access to 
the study and ultimately receive payment for completion, there were no obviously invalid 
responses  in the data set(all identical responses, skipping sections, etc). This suggests to the 




reliable as any other more traditional form of data collection. 
 The utilization of MTurk as a crowd sourcing data platform presents some limitations in 
the recruitment of a truly representative sample. Sheehan (2018) discussed that MTurk 
participants have an overrepresentation of Whites and Asians compared to the general population 
as well as being underemployed. However, similar arguments can be made about convenience 
sampling of college students which is an acceptable practice in social sciences research. There 
are also concerns previously discussed of misrepresentation to gain access to surveys for 
monetary compensation. While this practice is not new in social research, it may be more 
prevalent in samples recruited from MTurk as participants self-select into a group of online 
workers performing tasks and surveys for compensation. An effective way of mitigating these 
concerns is disguising the relevant screener questions with others as well as offering a paid 
screener to reduce misrepresentation for monetary gain (Sharpe Wessling et al., 2017). Analysis 
of demographics in the sample data, however, was consistent with previous research on this 
topic. This information suggests that while overrepresentation of certain groups may be present 
in MTurk samples, it’s effect was not perceptible on this data set with regards to consistency to 
other literature on this topic.  
Though research attempting to characterize the use of SCs is not new, prevalence has 
notably dropped from 7.4% to less than 1% since that time (Monitoring the Future, 2016; 
Vandrey et al., 2012). The present study is the first of its kind to investigate motivation for 
discontinuation of SC use beyond the scope of preference for marijuana. While useful to inform 
psychoeducational campaigns aimed at substance use prevention and harm reduction, it’s 
generalizability to other drug classes may be limited as SCs distinguish themselves as a unique 





Previous research had begun initial investigation into these factors as a component of 
their research, but data had never been collected with the specific purpose of understanding these 
underlying motivations for use in harm reduction strategies. Going beyond describing the 
differences in motivations between individuals who have made the decision to stop using 
synthetic cannabinoids and those that do, this study additionally quantified that there is likely a 
gap in general knowledge about synthetic cannabinoids among current and historical users. 
Importantly, addressing this gap may lead to more individuals electing to stop using this 
substance and result in reduced negative health outcomes associated with their use in the 
population.  
Psychoeducational programming has been used as a harm reduction method for many 
years in high profile programs such as D.A.R.E. programming in primary and secondary 
education settings. Though their effectiveness sometimes remains unclear, the current study’s 
data suggests that addressing this knowledge gap may be particularly effective for synthetic 
cannabinoids. Many factors may contribute to this somewhat unique position, including the 
notable complexity behind this class of designer drugs and the relative simplicity of which was 
advertised to the general public. Misinformation remains, including the notable amount of 
participants who indicated that synthetic cannabinoids are legal and utilize this assumed legal 
status as motivation to continue using these substances. Individuals reporting current use also 
demonstrated a higher trust for the purity and safety in production of synthetic cannabinoids, 
suggesting that information on the process of their production may be effective in persuading 
them to discontinue use.  




observed do not necessarily follow expected patterns when considering the information provided 
in chapter two. This could potentially be explained by the large variations observed in general 
knowledge about this substance class among current users versus those with a history of use. 
Lack of understanding and misinformation renders individuals unable to make informed 
decisions about the relative risk of synthetic cannabinoids when selecting a mind altering 
substance. Continued analysis of this data and additional comparisons may be made when 
interpreting these results in the context of specific groupings of users rather than the sample 
population as a whole. Also, these risk comparisons are limited only to those with any history of 
synthetic substance use, which may represent an immediate reduction in perceived danger in the 
sample population as a whole. Continued studies should focus on making comparisons between 
those with a history of use and non-users to draw inferences about the effects of risk perception.  
Additional research is first necessary to validate whether the motivating factors utilized in 
the survey items in the current study are adequately representative. While initial factor analysis 
results on the continuation and discontinuation questionnaires were favorable, validation studies 
will be necessary to utilize them in future studies drawing more specific conclusions. Similarly, 
while factor analysis results were favorable for the knowledge survey, additional information 
should be included in future studies to increase the reliability of the questionnaire and increase 
the scope of knowledge areas covered to more accurately determine what knowledge areas are 
most important when considering harm reduction. The study at hand has provided an outline to 
what may be effective harm reduction methods for synthetic cannabinoid use, however 
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Before we begin, we would like to make sure you qualify for our study. Please respond to the 
following questions. 
 
1. K2/Spice was sold in retail stores.  
True False 
2. K2/Spice doesn’t get you high.  
True False 
3. You can smoke K2/Spice  
True False 
4. I have never used K2/Spice (or other synthetic cannabinoid). 
True False  





































DEMOGRAPHIC INFORMATION  
 
1. What is your age?  _________ 
 
2. What is your gender? 
a. Male 
b. Female 
c. Non-binary/third Gender 
d. Prefer not to respond 
 
3. Are you Hispanic, Latino/a, or of Spanish origin? (one or more categories may be 
selected) 
a. No, not of Hispanic, Latino/a, or Spanish origin 
b. Yes, Mexican, Mexican American, Chicano/a 
c. Yes, Pureto Rican 
d. Yes, Cuban 
e. Yes, Another Hispanic, Latino/a or Spanish origin 
 
4. What is your race? (one or more categories may be selected) 
a. White 
b. Black or African American 
c. American Indian or Alaskan Native 
d. Asian 
e. Native Hawaiian or Pacific Islander 
f. Other 
 





6. What is your level of education? 
a. High School Education 
b. Some College 
c. Associate’s Degree 
d. Bachelor’s Degree 
e. Master’s Degree 
f. Professional Doctorate (MD, JD, DDS, DPT, etc.) 
g. Doctorate (PhD, Ed.D, etc.) 
 






8. Have you used K2/Spice in the past 30 days?  
Yes No 
 
9. Have you used alcohol in the past 12 months?  
Yes No 
 
10. Have you used alcohol in the past 30 days?  
Yes No 
 
11. Have you used tobacco products in the past 12 months?  
Yes No 
 
12. Have you used tobacco products in the past 30 days?  
Yes No 
 
13. Have you used marijuana in the past 12 months?  
Yes No 
 
14. Have you used marijuana in the past 30 days?  
Yes No 
 
15. Have you used any other illicit drugs in the past 12 months?  
Yes No 
 



























DISCONTINUATION OF SYNTHETIC CANNABINOID USE QUESTIONNAIRE 
 
On the following items, please indicate your responses as yes or no, considering why you have 
stopped using K2/Spice or have considered stopping using K2/Spice: 
 
Q1. I have quit using K2/Spice or considered quitting K2/Spice because… 
 
1. It could harm my physical health  
Yes No 
 
2. I’ve seen stories in the news about K2/Spice being dangerous  
Yes No 
 
3. I’ve had a bad personal experience with K2/Spice  
Yes No 
 
4. I read online that K2/Spice is dangerous  
Yes No 
 
5. I’ve seen or heard about friends have bad experiences using K2/Spice  
Yes No 
 
6. My friends have told me that K2/Spice is dangerous  
Yes No 
 
7. My parents have told me that K2/Spice is dangerous  
Yes No 
 
8. I would rather use marijuana  
Yes No 
 
9. I would rather use alcohol  
Yes No 
 
10. I would rather use other drugs  
Yes No 
 
11. I am worried about their impact on my mental health  
Yes No 
 







13. K2/Spice is difficult to obtain  
Yes No 
 
14. K2/Spice in unnatural  
Yes No 
 
15. I’m unsure what K2/Spice does to my body  
Yes No 
 
16. I didn’t/don’t enjoy using K2/Spice  
Yes No 
 
17. I think K2/Spice is addictive  
Yes No 
 
18. I don’t know where K2/Spice comes from or how its made  
Yes No 
 
19. I don’t know what K2/Spice actually is  
Yes No 
 






























CONTINUATION OF SYNTHETIC CANNABINOID USE QUESTIONNAIRE 
 
I would consider using K2/Spice again or I continue to use K2/Spice because… 
 
1. K2/Spice isn’t detected in drug screening/urine tests  
Yes/ No 
 
2. I enjoy using K2/Spice  
Yes/ No 
 
3. K2/Spice is safer than other drugs or alcohol  
Yes/ No 
 
4. My friends enjoy using K2/Spice  
Yes/ No 
 
5. K2/Spice is affordable to me  
Yes/ No 
 
6. K2/Spice is easy to obtain  
Yes/ No 
 
7. K2/Spice is legal  
Yes/ No 
 
8. I trust where K2/Spice comes from and that it is made responsibly  
Yes/ No 
 
9. I trust that K2/Spice is pure  
Yes/ No 
 


















SYNTHETIC CANNABINOID KNOWLEDGE QUESTIONNAIRE 
 
Please respond to these questions by either selecting true or false: 
 
1. There is only one type of K2/Spice, the different brands are all the same.  
True False 
 
2. K2/Spice is legal  
True False 
 
3. No one has died from using K2/Spice  
True False 
 
4. No one has been hospitalized from using K2/Spice  
True False 
 
5. No one has had suffered permanent damage from using K2/Spice  
True False 
 
6. No one has had mental health problems after using K2/Spice  
True False 
 
7. K2/Spice is detectable in drug tests/urine screens  
True False 
 
8. K2/Spice works in the same way as marijuana  
True False 
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Table 1. Age, Gender, Ethnicity, Race, Employment Status, Education, Synthetic 
Cannabinoid Use 
 
Demographic Characteristics Frequency (%) 
  
Age  
      18-24 41 (13.8%) 
      25-34 175 (59.1%) 
      35-44 45 (15.5%) 
      45-54 46 (15.5%) 
      55-64 11 (3.7%) 
  
Gender  
      Male 163 (55.1%) 
      Female 129 (43.6%) 
      Non-binary/third gender 2 (0.7%) 
  
Ethnicity  
      Not Hispanic / Latino/a 234 (79.1%) 
      Mexican, Mexican American, Chicano/a 29 (9.8%) 
      Puerto Rican 11 (3.7%) 
      Cuban 4 (1.4%) 





      White/Caucasian 240 (81.1%) 
      Black or African American 22 (7.4%) 
      American Indian or Alaskan Native 5 (1.7%) 
      Asian 31 (10.5%) 
      Native Hawaiian or Pacific Islander 2 (0.7%) 
      Other 2 (0.7%) 
  
Employment Status  
      Employed 253 (85.5%) 
      Unemployed 22 (7.4%) 
      Student 16 (5.4%) 
  
Education  
      High School Education 35 (11.8%) 
      Some College 55 (18.6%) 
      Associate’s Degree 37 (12.5%) 
      Bachelor’s Degree 139 (47.0%0 




      Professional Doctorate (MD, JD, etc) 2 (0.7%) 
      Doctorate (PhD, Ed.D, etc) 3 (1.0%) 
  
Synthetic Cannabinoid Use History  
      SC Use In Last 12 Months 148 (50.0%) 
      SC Use In Last 30 Days 70 (32.7%) 
  
Alcohol Use History  
      Alcohol Use in Last 12 Months 224 (75.7%) 
      Alcohol Use in Last 30 days 194 (65.5%) 
  
Tobacco Use History  
      Tobacco use in Last 12 Months 176 (59.5%) 
      Tobacco Use in Last 30 Days 153 (51.7%) 
  
Marijuana Use History  
      Marijuana Use in Last 12 Months 201 (67.9%) 
      Marijuana Use in Last 30 Days 165 (55.7%) 
  
Other Illicit Drug Use History  
      Other Drug Use in Last 12 Months 93 (32.1%) 































Chi Squared Tests of Association 
Discontinuing Use Items  χ2(1) p φ p 
I would rather use other drugs 12.177 .000 0.203 .000 
K2/Spice is difficult to obtain 6.401 .011 0.148 .000 
I’m unsure what K2/Spice does to my body 6.291 .012 -0.146 .000 
I didn’t/don’t enjoy using K2/Spice 12.655 .000 -0.207 .000 
I don’t know where K2/Spice comes from 11.690 .001 -0.199 .000 

































Chi Squared Tests of Association 
Continued Use Items  χ2(1) p φ p 
K2/Spice isn’t detected in drug screening tests 14.207 .000 0.219 .000 
I enjoy using K2/Spice 59.184 .000 0.449 .000 
K2Spice is safer than other drugs or alcohol 48.303 .000 0.406 .000 
My Friends Enjoy using K2/Spice 44.517 .000 0.389 .000 
K2/Spice is affordable to me 22.951 .000 0.279 .000 
K2/Spice is easy to obtain 17.464 .000 0.243 .000 
K2/Spice is legal 16.063 .000 0.234 .000 
I trust where K2/Spice comes from 57.911 .000 0.443 .000 
I trust that K2/Spice is pure 38.466 .000 0.362 .000 

























Relative Risk Comparison Data 
Substance Class Average Danger Rating Difference from SC Total Responses (n) 
Synthetic Cannabinoids 6.6294 * 286 
Tobacco 6.5171 -0.1303 284 
Alcohol 6.4399 -0.1555 283 
Marijuana 3.1254 -3.5054 279 
Inhalants 6.7057 0.1309 275 
LSD 5.6272 -0.9596 272 
PCP 7.1697 0.5827 266 
Ecstasy 5.9386 -0.6593 276 
Bath Salts 7.2288 0.6180 267 
Cocaine 6.8648 0.1709 275 
Crack 7.3794 0.7309 275 
Heroin 7.9894 1.3297 276 
Methamphetamine 7.6547 1.0696 273 
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